Overview

Bioequivalence Study of Perampanel Tablets 12 mg

Status:
COMPLETED
Trial end date:
2023-12-05
Target enrollment:
Participant gender:
Summary
An open-label, balanced, randomized, two treatment, two sequence, two period, two way cross-over, single dose bioequivalence study of Perampanel Tablets 12 mg of Humanis Sağlık A.ġ., Turkey and Fycompa 12 mg film-coated tablets of Eisai GmbH Edmund-Rumpler-Straße 3 60549 Frankfurt am Main Germany in normal, healthy, adult, human subjects under fasting condition.
Phase:
PHASE1
Details
Lead Sponsor:
Humanis Saglık Anonim Sirketi
Treatments:
perampanel